Xenon Pharmaceuticals (XENE) Seeks Epilepsy Approval. Can its Drug Overcome a Depression Setback?
Xenon Pharmaceuticals Inc XENE
$36.94
โผ -2.94%
($-1.12)
Open
$38.10
Prev Close
$38.06
Day Range
$36.48 โ $38.26
52W Range
$35.97 โ $72.66
Market Cap
$6.20B
Beta
0.08
EPS (TTM)
$-4.74
๐ Company Profile
| Industry | Biotechnology |
| Country | CA |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2014-10-17 |
| Shares Out. | 96,670,000 |
| Website | xenon-pharma.com/ โ |
| Phone | 16044843300 |
| Employees | 370 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$110.7M |
| Free Cash Flow | -$338.5M |
| Total Assets | $1.30B |
| Total Liabilities | $53.4M |
| Equity | $1.24B |
About Xenon Pharmaceuticals Inc
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
Xenon Pharmaceuticals Inc is a publicly traded company under the ticker symbol XENE on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
๐ Analyst Ratings
26 analysts (2026-09-01)
๐ฐ Latest News for XENE
Xenon Pharmaceuticals: Azetukalner Still Has Potential As An Epilepsy Candidate
Xenon stock lost 30%, but the FDA story is more complicated
Xenon to Present at TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
Company News for Sep 21, 2026
Xenon Pharmaceuticals Stock Sinks 31% After Pausing Depression Study Enrollment
Triple Witching Whipsaws Wall Street While Crypto Stocks Steal the Show
Why Xenon Pharmaceuticals (XENE) Is Down 32.2% After Pausing Psychiatry Trials Despite Positive NDA Data

